드러그인포 약품요약정보

허가정보

항목

내용

청구코드(KD코드)
비급여점검코드
상한금액

[A37002731] [보험코드에 따른 약품기본정보 직접조회]

\0 원/1정(2002.04.01)(현재약가)
[상병코드조회]
[질병코드조회]

빠른조회


요약정보	[효능] [용법] [금기] [신중투여] [이상반응]

상세정보	[효능] [용법] [경고] [금기] [신중투여] [이상반응] [일반주의] [상호작용] [임산부] [수유부] [소아] [고령자] [신장애환자] [간장애환자] [적용주의] [과량투여] [임상검사치] [보관] [기타]

효능효과

[적응증 별 검색]

급.만성 감염성 비염, 알러지성 비염, 비충혈, 유행성 비인두염, 이관 카타르, 급만성 부비강염, 비점막 치료 후의 회복촉진, 코감기, 고초열
[Drugbank 의 성분정보열람]
[Phenylpropanolamine]

용법용량

* 절대 임의복용하지 마시고 반드시 의사 또는 약사와 상담하시기 바랍니다.

[처방약어]
[주성분코드:259300ATB 에 따른 심사지침열람]
성인: 1일 3회, 1회 1정을 매 식전에 복용
소아(12세 이상): 1일 2-3회, 1회 1정을 식전에 복용

[BMI지수 계산] [Body Surface Area 계산] [Cockcroft-Gault GFR 계산] [MDRD GFR 계산]

[피해야 할 음식] [복용을 잊은 경우 대처법]

금기

녹내장, 전립선염, MAO저해제를 투여받고 있는 환자
이 약은 염산페닐프로판올아민을 함유하고 있으므로 염산페닐프로판올아민을 함유한 다른 약물(감기약, 비염용약, 진해거담제등)을 투여받고 있는 환자에는 투여하지 않는다.

이상반응

정신신경계 : 출혈성 뇌졸증, 어지러움, 불면, 심한 두통, 신경과민을 일으킬 수 있다.
순환기계 : 심계항진을 일으킬 수 있다.
소화기계 : 구역, 구토, 변비, 식욕부진이 나타날 수 있다.

기타 : 발진, 발적, 배뇨장애가 나타날 수 있다.

[주요 이상반응정보]

Related FDA Approved Drug

기준 성분:PHENYLPROPANOLAMINE HYDROCHLORIDE
BIPHETAP (BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
BROMANATE (BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
BROMANATE DC (BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
BROMATAPP (BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HYDROCHLORIDE (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HYDROCHLORIDE (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
CODAMINE (HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
COLD CAPSULE IV (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
COLD CAPSULE V (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
CONTAC (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
CONTAC 12 HOUR (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
DEMAZIN (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
DIMETANE-DC (BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
DIMETAPP (BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
DRIZE (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
HYCOMINE (HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
HYCOMINE PEDIATRIC (HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
MYPHETANE DC (BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
ORNADE (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
PHENYLPROPANOLAMINE HYDROCHLORIDE W/ CHLORPHENIRAMINE MALEATE (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
TAVIST-D (CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
TRIAMINIC-12 (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
기준 성분:DIPHEXAMIDE METHIODIDE
기준 성분:CHLORCINNAZINE 2HCL

정보요약

드럭인포 의약품 요약/상세정보

코드 및 분류정보

항목	내용
BIT 약효분류	비염 & 콧물약 (Decongestants & Nasal Prep.)
ATC 코드	Phenylpropanolamine, combinations / R01BA51 [코드분류상세설명] [ATC코드예측]
복지부분류코드	141 (항히스타민제 )
주성분코드 분석 및 중복처방 검토	[주성분코드 분석 및 중복처방 검토]
Drugs By Indication	[전체보기]
Drugs By Classification	[전체보기]

제품정보

항목	내용
청구코드(KD코드) 비급여점검코드 상한금액	[A37002731] [보험코드에 따른 약품기본정보 직접조회] \0 원/1정(2002.04.01)(최신약가) [상병코드조회] [질병코드집 다운로드]

복약정보

항목

내용

LACTmed 바로가기

[바로가기]

약리작용

유료정보입니다.

복약지도

유료정보입니다.

Pharmacokinetics

유료정보입니다.

병용금기 및 연령대금기 근거조회

[병용금기 및 연령대금기 근거조회]

복약라벨

이미지

복약설명

변비가 생길수 있습니다.

어지러움이 있을수 있습니다.

*	복약이미지는 모든 복약지도 사항을 표시한것은 아니며, 추가적으로 업데이트되거나 수정될 수 있습니다.
*	복약이미지의 표시여부는 실제 약물복용시 중요도에 따른것은 아니며 단순히 허가정보상 키워드를 기준으로 등록되었습니다.
*	귀하가 복약이미지 정보를 신뢰함은 전적으로 귀하의 책임입니다. 드럭인포는 이에 대한 어떠한 보증도 하지 않습니다.

보관상 주의

조제시 주의

심사정보

항목	내용
DUR 관련 고시	[병용연령금기 의약품 / 임부금기 의약품 / 비용효과적 함량 의약품 / 안전성 관련 급여중지 의약품]

학술정보

항목	내용
DUR (의약품사용평가)	병용금기 : 고시된 병용금기 내용은 없습니다. [상호작용/병용금기검색] 연령대금기 : 고시된 연령금기 내용은 없습니다. [연령대금기상세검색]
Mechanism of Action	Phenylpropanolamine에 대한 Mechanism_Of_Action 정보 Phenylpropanolamine acts directly on alpha- and, to a lesser degree, beta-adrenergic receptors in the mucosa of the respiratory tract. Stimulation of alpha-adrenergic receptors produces vasoconstriction, reduces tissue hyperemia, edema, and nasal congestion, and increases nasal airway patency. PPA indirectly stimulates beta-receptors, producing tachycardia and a positive inotropic effect.
Pharmacology	Phenylpropanolamine에 대한 Pharmacology 정보 Phenylpropanolamine (PPA), a sympathomimetic agent structurally similar to pseudoephedrine, is used to treat nasal congestion. Phenylpropanolamine is found in appetite suppressant formulations and with guaifenesinin in cough-cold formulations. In 2000, the FDA requested that all drug companies discontinue marketing products containing phenylpropanolamine, due to an increased risk of hemorrhagic stroke in women who used phenylpropanolamine.
Metabolism	Phenylpropanolamine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Monoamine oxidase type A (MAO-A)
Protein Binding	Phenylpropanolamine에 대한 단백결합 정보 Not Available
Half-life	Phenylpropanolamine에 대한 반감기 정보 2.1 to 3.4 hours.
Absorption	Phenylpropanolamine에 대한 Absorption 정보 Reduced bioavailability (about 38%) from gastrointestinal tract because of first pass metabolism by monoamine oxidase in the stomach and liver.
Pharmacokinetics	Phenylpropanolamine HCl의 약물동력학자료 흡수 : 경구 : 잘 흡수됨 생체내이용률 : 거의 100% 대사 : 간에서 norephedrine으로 대사됨 반감기 : 4.6-6.6 시간 소실 : 주로 미변화체로서(80-90%) 뇨를 통해 배설됨
Biotransformation	Phenylpropanolamine에 대한 Biotransformation 정보 Hepatic
Toxicity	Phenylpropanolamine에 대한 Toxicity 정보 May induce ventricular extrasystoles and short paroxysms of ventricular tachycardia, a sensation of fullness in the head and tingling of the extremities; LD₅₀=1490mg/kg (orally in rat)
Drug Interactions	Phenylpropanolamine에 대한 Drug_Interactions 정보 Acetophenazine Decreased anorexic effect, may increase psychotic symptomsChlorpromazine Decreased anorexic effect, may increase psychotic symptomsEthopropazine Decreased anorexic effect, may increase psychotic symptomsFluphenazine Decreased anorexic effect, may increase psychotic symptomsMethotrimeprazine Decreased anorexic effect, may increase psychotic symptomsGuanethidine The agent decreases the effect of guanethidineMesoridazine Decreased anorexic effect, may increase psychotic symptomsThioridazine Decreased anorexic effect, may increase psychotic symptomsMethdilazine Decreased anorexic effect, may increase psychotic symptomsTrimeprazine Decreased anorexic effect, may increase psychotic symptomsPropericiazine Decreased anorexic effect, may increase psychotic symptomsPerphenazine Decreased anorexic effect, may increase psychotic symptomsProchlorperazine Decreased anorexic effect, may increase psychotic symptomsPromazine Decreased anorexic effect, may increase psychotic symptomsPromethazine Decreased anorexic effect, may increase psychotic symptomsPropiomazine Decreased anorexic effect, may increase psychotic symptomsThiethylperazine Decreased anorexic effect, may increase psychotic symptomsTrifluoperazine Decreased anorexic effect, may increase psychotic symptomsTriflupromazine Decreased anorexic effect, may increase psychotic symptomsMoclobemide Moclobemide increases the sympathomimetic effectAmitriptyline The tricyclic increases the sympathomimetic effectAmoxapine The tricyclic increases the sympathomimetic effectBromocriptine The sympathomimetic increases the toxicity of bromocriptineClomipramine The tricyclic increases the sympathomimetic effectDesipramine The tricyclic increases the sympathomimetic effectDoxepin The tricyclic increases the sympathomimetic effectImipramine The tricyclic increases the sympathomimetic effectNortriptyline The tricyclic increases the sympathomimetic effectProtriptyline The tricyclic increases the sympathomimetic effectTrimipramine The tricyclic increases the sympathomimetic effectVenlafaxine Risk of serotoninergic syndromeFluvoxamine Risk of serotoninergic syndromeParoxetine Risk of serotoninergic syndromeFluoxetine Risk of serotoninergic syndromeAlseroxylon Increased arterial pressureDeserpidine Increased arterial pressureIsocarboxazid Increased arterial pressureLinezolid Possible increase of arterial pressureTranylcypromine Increased arterial pressureRasagiline Increased arterial pressureReserpine Increased arterial pressurePhenelzine Increased arterial pressurePargyline Increased arterial pressureMethyldopa Increased arterial pressureMidodrine Increased arterial pressure
CYP450 Drug Interaction	[CYP450 Table직접조회]
Food Interaction	Phenylpropanolamine에 대한 Food Interaction 정보 Take without regard to meals.Limit caffeine intake.
Drug Target	[Drug Target]
Description	Phenylpropanolamine에 대한 Description 정보 Phenylpropanolamine has been withdrawn in Canada. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug.
Dosage Form	Phenylpropanolamine에 대한 Dosage_Form 정보 Not Available
Drug Category	Phenylpropanolamine에 대한 Drug_Category 정보 Adrenergic alpha-AgonistsAppetite DepressantsNasal DecongestantsSympathomimetics
Smiles String Canonical	Phenylpropanolamine에 대한 Smiles_String_canonical 정보 CC(N)C(O)C1=CC=CC=C1
Smiles String Isomeric	Phenylpropanolamine에 대한 Smiles_String_isomeric 정보 C[C@@H](N)[C@@H](O)C1=CC=CC=C1
InChI Identifier	Phenylpropanolamine에 대한 InChI_Identifier 정보 InChI=1/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m1/s1
Chemical IUPAC Name	Phenylpropanolamine에 대한 Chemical_IUPAC_Name 정보 (1S,2R)-2-amino-1-phenylpropan-1-ol

사용자컨텐츠

항목

내용

핵심 요약 정보